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Interleukin 18 (IL-18), a member of the IL-1 family of cytokines, is an important regulator of innate
and acquired immune responses. It signals through its ligand-binding primary receptor IL-18Ra and
accessory receptor IL-18Rb. Here we report the crystal structure of IL-18 with the ectodomain of IL-
18Ra, which reveals the structural basis for their speciﬁc recognition. It conﬁrms that surface charge
complementarity determines the ligand-binding speciﬁcity of primary receptors in the IL-1 receptor
family. We suggest that IL-18 signaling complex adopts an architecture similar to other agonistic
cytokines and propose a general ligand-receptor assembly and activation model for the IL-1 family.
Structured summary of protein interactions:
IL-18 and IL-18R alpha bind by x-ray crystallography (View interaction)
IL-18R alpha and IL-18 bind by molecular sieving (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction chain (IL-18Rb) on the surface of target cells to activate down-Interleukin 18 (IL-18) is an important cytokine participating in
the regulation of innate and acquired immune responses [1–3].
Pleiotropic effects of IL-18, especially the induction of IFN-c from
T cells and natural killer cells in synergy with IL-12 [4,5], are essen-
tial for immunity against invading pathogens [6]. However, the
overproduction of IL-18 has been implicated in several autoim-
mune and chronic inﬂammatory disorders including rheumatoid
arthritis, system lupus erythematosus, psoriasis, and inﬂammatory
bowel disease in experimental animal models and clinical situa-
tions [7–9].
IL-18 is a member of the IL-1 family because of its structural
homology, receptor utilization, signal transduction pathways, and
biological effects [10]. IL-18 production has been detected from a
variety of immune and non-immune cells including monocytes,
macrophages, dendritic cells, epithelial cells, keratinocytes, and
synovial ﬁbroblasts [3]. Similar to IL-1b, IL-18 is ﬁrst synthesized
as a 23kDa inactive precursor (pro-IL-18), which is cleaved by cas-
pase-1 to release the 18kDa active mature protein [2]. IL-18 binds
to the IL-18 receptor alpha chain (IL-18Ra) and IL-18 receptor betastream NF-jB and MAPK pathways, which induce a variety of
inﬂammatory cytokines [11]. IL-18Ra is the primary receptor
responsible for speciﬁc binding of IL-18, whereas IL-18Rb, an
accessory co-receptor, does not directly bind to IL-18 but is
required for signaling. Both receptors are members of the IL-1
receptor family, with an extracellular domain comprising three
Ig-like domains, a transmembrane helix, and an intracellular
Toll-IL-1R (TIR) domain responsible for signal transduction [11].
The agonistic cytokines in the IL-1 family include IL-1a, IL-1b,
IL-18, IL-33, IL-36a, IL-36b, and IL-36c [10]. IL-18 has its own spe-
ciﬁc co-receptor IL-18Rb, whereas others all use IL-1 receptor
accessory protein (IL-1RAcP) as the co-receptor in their respective
signaling complexes. Our and other groups have revealed the
structural basis for the interactions of IL-1b and IL-33 with their
respective primary receptor and co-receptor IL-1RAcP [12–14],
which helps establish a stepwise ligand-receptor assembly and
activation model for the IL-1RAcP-dependent cytokines [13]. In this
model, ligand recognition relies on the interaction of cytokine with
its primary receptor: IL-1a and IL-1b with IL-1RI, IL-33 with ST2,
and IL-36a, IL-36b, and IL-36c with IL-1Rrp2. The binding of
cytokine with primary receptor forms a composite surface to
recruit IL-1RAcP to form the ternary signaling complex [13]. Crys-
tal structures of IL-18 with its receptors have not been reported.
Therefore, the structural basis for the speciﬁc recognition of IL-18
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bly of IL-18Rb in the IL-18 signaling complex is similar to the
assembly of IL-1RAcP in the signaling complexes of other agonistic
cytokines. To answer these questions and gain a complete under-
standing of ligand-receptor interaction and activation in the IL-1
family, we determined the crystal structure of human IL-18 in
complex with the ectodomain of IL-18Ra.
2. Materials and methods
2.1. Gene cloning, protein expression and puriﬁcation
The cDNA encoding pro-IL-18 with four Cys mutated to Ser was
cloned into pGEX-6p-1 vector with an N-terminal GST tag. The
GST-pro-IL-18 fusion protein was expressed in Escherichia coli
BL21 (DE3) by induction with 0.5 mM IPTG at 0.6–0.8 OD600 in
overnight cultures grown at 289 K. The cells were harvested by
centrifugation and suspended with lysis buffer containing 50 mM
Tris, pH 8.0, and 500 mMNaCl. After sonication, the lysate was cen-
trifuged at 13000 rpm for 1 h, and the supernatant was transferred
to Glutathione Sepharose 4B column. After extensive wash of col-
umn with lysis buffer, the bound GST-pro-IL-18 was digested on
column with caspase-1 overnight at 277 K. The released mature
IL-18 was collected and further puriﬁed by gel-ﬁltration chroma-
tography using the Superdex 200 High Performance column (GE
Healthcare) and the running buffer was the same as lysis buffer.
The ectodomain of IL-18Ra (residues 19–329) was expressed in
Spodoptera frugiperda Sf9 insect cells by using the Bac-to-Bac bac-
ulovirus expression system (Invitrogen). Sf9 insect cells were
maintained in Insect-Xpress protein-free medium (Lonza) without
serum at 300 K. The cDNA encoding the IL-18Ra ectodomain was
cloned into pFastBac vector with an N-terminal gp67 signal pep-
tide to facilitate secretion and a C-terminal His-tag to facilitate
puriﬁcation. The plasmid was transformed into bacterial DH10Bac
competent cells, and the extracted bacmid was transfected into Sf9
cells in the presence of Cellfectin II reagent (Invitrogen). After incu-
bation of the transfected cells at 300 K for 7 d, the low-titer baculo-
viruses were harvested by collecting the supernatant of cell culture
with centrifugation at 2000 rpm for 10 min. After two rounds of
ampliﬁcation, the high-titer viruses were used to infect Sf9 cells
at a density of 2  106 cells per milliliter. The supernatant of cell
culture containing the IL-18Ra ectodomain was harvested 60 h
after infection, and concentrated and buffer-exchanged to HBS buf-
fer containing 10 mM HEPES, pH 7.2, and 150 mM NaCl. The IL-
18Ra ectodomain was captured with nickel-beads, eluted with
500 mM imidazole in HBS buffer, and puriﬁed by gel-ﬁltration
chromatography using the Superdex 200 High Performance col-
umn (GE Healthcare) with the HBS running buffer. The puriﬁed
IL-18Ra ectodomain was digested with Endoglycosidase H and F1
at room temperature overnight and further puriﬁed by gel-ﬁltra-
tion chromatography. To obtain the IL-18-IL-18Ra binary complex,
puriﬁed IL-18 and IL-18Ra ectodomain were mixed on ice for 1 h
and puriﬁed by gel-ﬁltration chromatography using the Superdex
200 High Performance column (GE Healthcare) with the HBS run-
ning buffer.
2.2. Crystallization and data collection
The crystals of IL-18-IL-18Ra complex were grown at 291 K by
vapor diffusion in sitting drops composed of equal volumes of pro-
tein solution (10 mg/mL in 10 mM HEPES, pH 7.2, and 150 mM
NaCl) and reservoir solution (20% polyethylene glycol 3350,
0.03 M citric acid, 0.07 M Bis–Tris propane, pH 7.6). All crystals
were cryoprotected by soaking in reservoir solution supplemented
with 20% glycerol for several seconds and then cooled in liquidnitrogen. Diffraction data were collected on beam line BL17U at
the Shanghai Synchrotron Research Facility (SSRF) and processed
with HKL2000 [15].
2.3. Structure determination and reﬁnement
A molecular replacement solution of IL-18 was determined with
the program PHASER using the IL-18 NMR solution structure (PDB
code 1J0S) as the search model [16,17]. The positions of the D1D2
module and D3 domain of IL-18Ra were also determined with the
program PHASER using the D1D2 module and D3 domain of IL-1RI
(PDB code 1ITB) as search models [17,18]. There are two IL-18-IL-
18Ra complexes in the asymmetric unit, and non-crystallographic
symmetry restraints were used in the subsequent structural reﬁne-
ment. Iterative reﬁnement with the program PHENIX and model
building with the program COOT were conducted [19,20], yielding
a ﬁnal model with Rwork of 23.3% and Rfree of 28.2%. The quality of
the model was validated with the program PROCHECK [21], and all
structure ﬁgures were made with the program PYMOL [22].
3. Results and discussion
3.1. Overall structure
It has been reported that the N-terminal pro-peptide is essential
for the correct folding of IL-18 expressed in bacteria to obtain full
activity [23]. In previous studies, all Cys residues in IL-18 were
mutated to Ala or Ser to prevent polymerization through the oxida-
tion of surface-exposed Cys74 and Cys104, and these mutants
retained the biological activities as wild type IL-18 [24,25]. There-
fore, we ﬁrst expressed and puriﬁed human pro-IL-18 (193 resi-
dues) with an N-terminal GST tag in bacteria, in which four Cys
residues in the mature IL-18 region were mutated to Ser. The
mature IL-18 was obtained by cleavage with caspase-1 to remove
the 36-residue pro-peptide (Fig. S1A). The puriﬁed IL-18 (residues
Tyr1-Asp157) bound to human IL-18Ra ectodomain (residues
Ala19-Arg329), which was expressed and puriﬁed from insect cells,
to form the IL-18-IL-18Ra complex (Fig. S1B). The crystal structure
of the complex was determined by the molecular replacement
method at a resolution of 2.8 Å (Table 1). The ﬁnal model in the
asymmetric unit contains two IL-18-IL-18Ra complexes
(Fig. S2A), with residues Tyr1-Asn155 in IL-18 and residues
Ser21-Cys43, Thr51-Arg71, Arg75-Leu161, Pro169-GLu253, and
Asn260-Asp318 in IL-18Ra. The electron density map allows us
to visualize N-acetyl-D-glucosamine (NAG) attached to residues
Asn197, Asn203, Asn236, and Asn297 of IL-18Ra (Fig. 1). Two com-
plex structures in the asymmetric unit are very similar with a r.m.s.
deviations of 0.33 Å for all 430 C a atoms (Fig. S2B). Therefore, we
use one IL-18-IL-18Ra complex structure in the subsequent
description and discussion.
IL-18Ra has a curved shape with three Ig-like domains (D1 to
D3) (Fig. 1). The D1 and D2 domains pack together to form a
D1D2 module, to which the D3 domain is connected through a lin-
ker (Fig. 1). The overall architecture of IL-18Ra is very similar to
those of IL-1RI and ST2, especially at the D1D2 module (Fig. S3A).
The D3 domain is more ﬂexible in its position related to the
D1D2 module (Fig. S3B), reﬂecting the intrinsic domain-level con-
formation ﬂexibility of D3 in ligand binding by primary receptors
[13].
IL-18 in the complex adopts a b-trefoil fold comprised of 12
anti-parallel b-strands that are arranged in a threefold symmetric
pattern (Fig. 1). This fold is a conserved signature structure for
all IL-1 family of cytokines in spite of their low sequence similarity
in the range of 10–40% [26]. The solution structure of IL-18 has
been determined by NMRmethod [16]. Its complex structures with
Table 1
Crystallographic data collection and reﬁnement statistics.
Data collection
Beamline SSRF BL17U
Wavelength 0.9796 Å
Space group P21
Cell dimensions
a, b, c (Å) 71.39, 85.60, 88.12
a, b, c () 90, 97.60, 90
Resolution (Å) 50–2.80 (2.88–2.80)
Rmerge (%) 12.1 (61.3)
I/rI 10.5 (2.4)
Completeness (%) 97.5 (99.0)
Redundancy 2.9 (3.0)
Reﬁnement
Resolution (Å) 38.9–2.80 (2.91–2.80)
No. Reﬂections 25300 (2684)
Rwork/Rfree (%) 23.3/28.2
No. atoms
Protein 6989
Glycan 112
B-factors (Å2)
Protein 58.2
Glycan 54.8
r.m.s. deviations
Bond lengths (Å) 0.013
Bond angles () 1.799
Ramachandran plot (%)
Most favored 86.7
Additionally allowed 11.9
Generously allowed 1.3
Disallowed 0.1
Rwork and Rfree are deﬁned by R =Rhkl||Fobs|  |Fcalc||/Rhkl|Fobs|, where h, k, and l are
the indices of the reﬂections (used in reﬁnement for Rwork; 5%, not used in reﬁne-
ment for Rfree) and Fobs and Fcalc are the structure factors, deduced from intensities
and calculated from the model, respectively.
Fig. 1. Ribbon diagram of human IL-18 (green) in complex with the ectodomain of
IL-18Ra receptor (cyan). The observed NAGs linked to Asn197, Asn203, Asn236, and
Asn297 of IL-18Ra are colored in magenta.
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tein (IL-18BP) have also been determined by X-ray crystallography,
respectively [25,27]. Structural superimposition shows that the
twelve b-strands forming the b-trefoil core of IL-18 are conserved
in different states, whereas conformational variations reside in
the loops connecting the strands, especially at the b3-b4, b4-b5,
and b11-b12 loops (Fig. S4). These loops are involved in theinteraction with receptors, and their roles will be described and
discussed below.
3.2. Interactions between IL-18 and IL-18Ra
With the inner surface of the curved shape, IL-18Ra binds IL-18
like a grasping hand with all three domains (Fig. 1). This binding
mode has also been observed in the recognition of IL-1b by IL-
1RI and IL-33 by ST2 (Fig. 2A) [13,14,18]. However, structural com-
parisons based on bound cytokine show that IL-18Ra is tilted 20
from IL-RI and ST2 in ligand binding (Fig. 2B).
The binding interface between IL-18 and IL-18Ra is composed
of two separate sites (Fig. 3). Site 1 between IL-18 and the D1D2
module of IL-18Ra has a buried surface of 845 Å2 (Fig. 3). Eleven
IL-18 residues from b1-b2 loop, b2 and b3 strands, and b3-b4 and
b10-b11 loops interact with the D1D2 module of IL-18Ra receptor
with a 3.5 Å distance cutoff (Fig. S5). There is a signiﬁcant confor-
mational change in the b3-b4 loop of IL-18 upon binding to IL-
18Ra. This loop extends away from the b-trefoil core in the
solution structure of free IL-18, and it pulls inward by 7 Å toward
the core and has a short helix (Asp35-Asn41) when IL-18 binds to
IL-18Ra (Figs. S4 and S5). Most of IL-18 residues involved in the
interaction with IL-18Ra, including Glu31, Asp32, Met33, Thr34,
Asp35, Asp37, Asp40, and Asn41, are adjacent to or in the helix
(Fig. S5). Hydrophilic interactions between side chains of contact-
ing residues dominate at site 1. These speciﬁc interactions include
hydrogen bonds (Glu31-Ser24, Thr34-Gln124, Asp35-Ser127, and
Asp40-Thr29) and salt bridges (Asp17-Lys128, Glu31-Arg25, and
Asp37-Arg25) (Fig. 3). Site 2 between IL-18 and the D3 domain of
IL-18Ra is relatively smaller with a buried surface of 603 Å2
(Fig. 3). Six IL-18 residues from b4, b5, and b8 strands interact with
the D3 domain of IL-18Ra (Fig. S5). Hydrophobic IL-18 residue
Met60 contacts with Ala301 of IL-18Ra. IL-18 residue Lys53 forms
a salt bridge with Glu253 of IL-18Ra (Fig. 3). The NAG glycans
linked to Asn197 and Asn236 of IL-18Ra are far away from IL-18
(>15 Å), whereas NAG glycans linked to Asn203 and Asn297 are
much closer with a distance of 4.5 Å to IL-18. The interactions
observed at the interface are consistent with previous mutagenesis
studies revealing that IL-18 residues Asp17, Met33, and Asp35 at
site 1 and Lys53 and Met60 at site 2 are important for in vitro bind-
ing with IL-18Ra and the activity to induce IFN-c [16,28,29].
IL-18 binding protein (IL-18BP) is a negative regulator of IL-18
signaling, which is not limited to just vertebrates, but also is
encoded by many poxviruses to participate in viral immune eva-
sion [2]. The ectromelia virus IL-18BP adopts a single Ig-fold and
interacts with IL-18 in a manner very similar to the D3 domain
of IL-18Ra (Fig. S6) [27], therefore directly blocking the binding
site 2 between IL-18 and IL-18Ra.
3.3. Surface charge complementarity at site 1
Primary receptors IL-18Ra and ST2 speciﬁcally recognize their
respectively ligands IL-18 and IL-33, whereas other primary recep-
tors IL-1RI and IL-1Rrp2 show ligand-binding promiscuity. IL-1RI
binds to agonistic IL-1a and IL-1b and antagonistic IL-1Ra, and
IL-1Rrp2 binds to agonistic IL-36a, IL-36b, and IL-36c [10].
Through studying the interaction of IL-33 with ST2, we previously
found that site 1 between IL-33 and ST2 has speciﬁc salt-bridge
interactions and surface charge complementarity, which are absent
at site 1 between IL-1a and IL-1RI and between IL-1b and IL-1RI
[13]. This leads us to suggest that ST2 mainly uses surface charge
complementarity at site 1 to achieve ligand-binding speciﬁcity
[13]. At site 1 between IL-18 and IL-18Ra, there is a continuous
negative-charge patch on the surface of IL-18 formed by acidic
Asp17, Glu31, Asp32, Asp35, Asp37, and Asp40 (Fig. 4). The corre-
sponding positive-charge patch on the surface of IL-18Ra D1D2
Fig. 2. The conserved binding mode between cytokine and primary receptor in the IL-1 family. (A) Structures of IL-18-IL-18Ra, IL-1b-IL-1RI (PDB code 1ITB), and IL-33-ST2
(PDB code 4KC3) complexes. (B) Tilted IL-18Ra (cyan) compared with IL-1RI (magenta) and ST2 (orange) when the structures are aligned based on bound cytokines.
Fig. 3. The binding interface between IL-18 and IL-18Ra is composed of two
binding sites. Site 1 is between IL-18 and the D1D2 module of IL-18Ra, and site 2 is
between IL-18 and the D3 domain of IL-18Ra. The zoom-in top panel shows the
speciﬁc hydrogen-bonding (yellow dash lines) and salt-bridge (black dash lines)
interactions between IL-18 and IL-18Ra at site 1. The zoom-in bottom panel shows
the hydrophobic and hydrophilic interactions at site 2. The Lys53-Glu253 salt
bridge is represented with a black dash line.
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(Fig. 4). Notably, IL-18 acidic residues Asp17 and Asp35 at site 1
are found to be important for the interaction with IL-18Ra and
the biological activities [16]. These results collectively indicate that
surface charge complementarity at site 1 also determines the spe-
ciﬁc recognition of IL-18 by IL-18Ra.
3.4. IL-18 signaling complex model
Through structural studies of IL-1b and IL-33 with their recep-
tors [12,13], we found that the initial binding of IL-1RAcP-depen-
dent cytokines by their respective primary receptors generates a
composite surface composed of the b4-b5 and b11-b12 loops of
cytokine and the D2 domain of primary receptor to further recruit
IL-1RAcP to form the ternary signaling complex. However, IL-18 is
the only agonistic cytokine in the IL-1 family that uses IL-18Rb
instead of IL-1RAcP as the signaling-essential co-receptor. How
the IL-18Rb is recruited to form the IL-18 signaling complex is still
not well understood in the absence of IL-18-IL-18Ra-IL-18Rb com-
plex structure. Here we show that the overall architecture of IL-18-
IL-18Ra is similar to the IL-1b-IL-1RI and IL-33-ST2 complexes that
recruit IL-1RAcP (Fig. 2A). This leads us to speculate that IL-18 sig-
naling complex would adopt a similar architecture as IL-1b and IL-
33 signaling complexes (Fig. 5A), in which the b4-b5 and b11-b12
loops of IL-18 are involved in the interaction with IL-18Rb (Fig. 5A).
IL-18-neutralizing monoclonal antibody 125-2H inhibits the
binding of IL-18 to L428 cells that have expression of IL-18Ra
but low expression of IL-18Rb [30]. Antibody 125-2H binds to IL-
18 with a large buried area of 2350 Å2, which is at the high end
Fig. 4. Surface electrostatic potential of IL-18 and IL-18Ra at binding site 1.
3842 H. Wei et al. / FEBS Letters 588 (2014) 3838–3843of antigen–antibody complexes [25]. The b8 strand, b4-b5, b8-b9,
b10-b11, and b11-b12 loops of IL-18 are involved in the interaction
with 125-2H, among which the b11-b12 is the primary contacting
loop containing anchor residue Leu144 (Fig. 5B) [25]. Structural
superimposition shows that 125-2H and IL-18Ra do have steric
clashes between the D2 domain of IL-18Ra and the VH domain of
125-2H heavy chain when they bind to IL-18 simultaneously
(Fig. 5B), which explains the inhibition of IL-18 binding to L428
cells by 125-2H [30].
Interestingly, antibody 125-2H does not potently inhibit the
binding of IL-18 to the TNF-a-primed KG-1 cells with high
expression of IL-18Ra and IL-18Rb, but it is still able to decrease
the production of IFN-c by KG-1 cells stimulated by IL-18 [30]. It
was proposed that the binding of IL-18Rb with IL-18 at site 3,
which contains IL-18 residues Lys79, Lys84, and Asp98 [16],
induces conformational changes of IL-18 and/or IL-18Ra [25,30].
These changes presumably allow the binding of 125-2H to formFig. 5. IL-18-IL-18Ra-IL-18Rb signaling complex model. (A) Left panel shows the structur
b11-b12 loops of IL-1b interact with IL-1RAcP. Right panel shows a model of the IL-18-IL-
18Ra crystal structures. (B) Structural superimposition of IL-18-IL-18Rawith IL-18-125-2
18Ra and VH domain of 125-2H heavy chain, as shown in the zoom-in panel. The b4-b5
interaction with 125-2H.an antibody-IL-18-IL-18Ra-IL-18Rb quaternary complex, however,
the relative positional changes of IL-18 and its receptors after bind-
ing of 125-2H make the quaternary complex unable to induce
downstream signaling as normal IL-18-IL-18Ra-IL-18Rb ternary
complex [25]. In our proposed IL-18-IL-18Ra-IL-18Rb complex
model, IL-18 interacts with IL-18Rb mainly through its b4-b5 and
b11-b12 loops (Fig. 5A). Therefore, the binding site 3 between IL-
18 and IL-18Rb in our proposed model is different from previously
proposed one containing IL-18 residues Lys79, Lys84, and Asp98
[16]. Notably, the b11-b12 is also the primary loop for 125-2H
interaction (Fig. 5B) [25]. Therefore, the formation of antibody-IL-
18-IL-18Ra-IL-18Rb quaternary complex in our model is unlikely.
The IL-18Ra and IL-18Rb heterodimers on TNF-a-primed KG-1
cells have much higher binding afﬁnity for IL-18 than IL-18Ra on
L428 cells [30]. Therefore, the inhibition of 125-2H would be com-
promised in the binding of IL-18 to KG-1 cells than to L428 cells
[30]. However, 125-2H would interfere with the stability of signal-
ing-competent IL-18-IL-18Ra-IL-18Rb complex by competing with
IL-18b, thereby inhibiting the biological activity of IL-18 on TNF-a-
primed KG-1 cells [30].3.5. Ligand-receptor assembly and activation in the IL-1 family
Based on results from the current and previous studies [12–
14,18], we suggest a general ligand-receptor assembly and
activation model in the IL-1 family. The signaling depends on the
recognition of cytokine by primary receptor and the subsequent
recruitment of co-receptor IL-1RAcP or IL-18Rb (Fig. S7A). The sig-
naling complexes in the IL-1 family adopt the ‘‘LEFT’’ architecture,
in which co-receptor binds to the preformed cytokine and primary
receptor from the left side, as seen from the concave surface of pri-
mary receptor (Fig. S7A).e of IL-1b-IL-1RI-IL-1RAcP ternary complex (PDB code 4DEP), in which the b4-b5 and
18Ra-IL-18Rb complex based on the determined IL-1b-IL-1RI-IL-1RAcP and IL-18-IL-
H (PDB code 2VXT) structures. There are steric clashes between the D2 domain of IL-
and b11-b12 we suggest to interact with IL-18Rb in the model are involved in the
H. Wei et al. / FEBS Letters 588 (2014) 3838–3843 3843The ‘‘LEFT’’ architecture is unique among various interleukins
that utilize single-transmembrane cell-surface receptors to
mediate their biological activities. The diverse members in the IL-
1 family use the ﬂexible loops in the b-trefoil fold to interact with
the concave surface of their primary receptors, and the convex face
of co-receptors IL-1RAcP or IL-18Rb is docked to the left side of the
cytokine-primary receptor complex (Fig. S7A). Divergent helical
interleukins with a helix-bundle core bind to receptors across the
type I and type II divisions of the hematopoietic superfamily
[31]. In contrast with the IL-1 family of cytokines, helical interleu-
kins use the helices to interact with the convex face of both pri-
mary receptor and shared co-receptor such as common gamma
chain and gp130 (Fig. S7B), focusing on the hinge region between
two Ig-like domains [31]. The binding sites between helical inter-
leukins and their receptors still have structural plasticity to accom-
modate sequence divergence and promiscuous interactions [31].
4. Conclusions
In summary, we report the crystal structure of IL-18 bound to
the ectodomain of IL-18Ra. Analyses of binding interface, together
with previous mutagenesis data, reveal critical residues for the
speciﬁc recognition of IL-18 by IL-18Ra. The structure also
conﬁrms that charge complementarity determines the ligand-
binding speciﬁcity of primary receptors IL-18Ra and ST2 in the
IL-1 receptor family. We ﬁnally propose that IL-18 signaling
complex adopts a ‘‘LEFT’’ architecture similar to the signaling com-
plexes of IL-1RAcP-dependent cytokines. Therefore, a stepwise
ligand-receptor assembly and activation model can be extended
to include IL-18 with its speciﬁc receptors IL-18Ra and IL-18Rb.
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